New hope for elderly leukemia patients: experimental combo trial launches

NCT ID NCT06389292

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This global phase 3 trial tests whether adding the experimental drug lisaftoclax to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have intensive chemotherapy will receive either the combo or a placebo plus azacitidine. The main goal is overall survival, with secondary measures of response rates and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lisaftoclax (APG-2575) combined with azacitidine
What this could lead to: If successful, this combination could offer a new treatment option that extends survival for elderly AML patients who cannot tolerate standard chemotherapy.
What could go wrong: This is a phase 3 trial, but the drug is still experimental. It may not improve survival or could cause side effects like low blood counts or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Botkin Moscow Multidisciplinary Research and Clinical Center
RECRUITING

Moscow, 125284, Russia
Hematology Hospital of the Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Leningrad Regional Clinical Hospital
RECRUITING

Saint Petersburg, 194291, Russia
Moscow Multidisciplinary Clinical Center "Kommunarka"
RECRUITING

Moscow, 108814, Russia
Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency
RECRUITING

Saint Petersburg, 191024, Russia
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.